These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 15603886)

  • 1. Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model.
    Manservigi R; Boero A; Argnani R; Caselli E; Zucchini S; Miriagou V; Mavromara P; Cilli M; Grossi MP; Balboni PG; Cassai E
    Vaccine; 2005 Jan; 23(7):865-72. PubMed ID: 15603886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
    J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
    Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
    FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
    Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB
    J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
    Quenelle DC; Collins DJ; Marciani DJ; Kern ER
    Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy.
    Mo A; Musselli C; Chen H; Pappas J; Leclair K; Liu A; Chicz RM; Truneh A; Monks S; Levey DL; Srivastava PK
    Vaccine; 2011 Nov; 29(47):8530-41. PubMed ID: 21767588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.
    Bagley KC; Schwartz JA; Andersen H; Eldridge JH; Xu R; Ota-Setlik A; Geltz JJ; Halford WP; Fouts TR
    Viral Immunol; 2017 Apr; 30(3):178-195. PubMed ID: 28085634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines for herpes simplex virus infections.
    Koelle DM
    Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
    Wang K; Goodman KN; Li DY; Raffeld M; Chavez M; Cohen JI
    J Virol; 2016 Jan; 90(1):562-74. PubMed ID: 26559846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
    Awasthi S; Huang J; Shaw C; Friedman HM
    J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the herpes simplex virus type 2 glycoprotein D in baculovirus expression system and evaluation of its immunogenicity in guinea pigs.
    Fotouhi F; Soleimanjahi H; Roostaee MH; Dalimi Asl A
    Iran Biomed J; 2008 Apr; 12(2):59-66. PubMed ID: 18506211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice.
    Jazayeri M; Soleimanjahi H; Fotouhi F; Pakravan N
    Comp Immunol Microbiol Infect Dis; 2009 Sep; 32(5):453-61. PubMed ID: 18571235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
    Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT
    J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease.
    Da Costa XJ; Bourne N; Stanberry LR; Knipe DM
    Virology; 1997 May; 232(1):1-12. PubMed ID: 9185583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity.
    Cortesi R; Argnani R; Esposito E; Dalpiaz A; Scatturin A; Bortolotti F; Lufino M; Guerrini R; Cavicchioni G; Incorvaia C; Menegatti E; Manservigi R
    Int J Pharm; 2006 Jul; 317(1):90-100. PubMed ID: 16600535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
    Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
    ; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
    Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
    Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE
    J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.